CTRI/2025/02/080336尚未招募2/3 期
Evaluation of the Effect of Montelukast Sodium and Levocetrizine on Serum Arginase Levels in Patients with Allergic Rhinitis in a Tertiary Care Center- A Randomized Controlled Trial
Vignesh S1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年2月22日最近更新:
试验速览
- 阶段
- 2/3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- To Evaluate serum arginase levels in allergic rhinitis patient
研究概览
简要总结
TO EVALUATE THE EFFECT OF LEVOCETRIZINE AND MONTELUKAST SODIUM ON SERUM ARGINASE LEVEL AND TOTAL NASAL SCORE PRE AND POST DRUG ADMINISTRATON BY ELISA METHOD
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- Participant Blinded
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Allergic rhinitis.
排除标准
- •Asthma Polyposis Systemic disease like eosinophilia Pregnancy.
结局指标
主要结局
To Evaluate serum arginase levels in allergic rhinitis patient
时间窗: 4 WEEKS
次要结局
- To Evaluate total nasal scores(4 WEEKS)
研究者
Vignesh S
SRM Medical College Hospital and Research Centre
研究点 (1)
Loading locations...
相似试验
招募中
4 期
DiEtary Sodium Intake effects on ertugliflozin-induced changes in GFR, reNal oxygenation and systemic hemodynamics: the DESIGN study, a randomized, placebo-controlled, cross-over study with ertugliflozin in people with type 2 diabetes.2023-510257-42-01Amsterdam UMC17
尚未招募
不适用
To find out how well Saroglitazar helps improve fatty liver disease and manage related problems like high cholesterol, blood sugar, and weight in people with metabolic syndrome.CTRI/2025/02/08023085
招募中
4 期
EFFECT OF THE USE OF DAPAGLIFLOZIN IN DIURESIS, NATRIURIESIS AND IN ULTRAFILTRATION AND PERITONEAL ELIMINATION OF SODIUM, IN PATIENTS WITH REFRACTORY HEART FAILURE (DAPA-DP study)2023-505571-78-00Instituto de Investigacion Sanitaria Fundacion para la Investigacion del Hospital Clinico de Valencia-INCLIVA1
尚未招募
不适用
Clinical study of Tiktadi Ghrita Ointment on stretchmarks in pregnant womenCTRI/2024/12/078715Dr Alka Gajanan Khade64
已完成
3 期
Study to Evaluate Safety, Tolerability and Efficacy in patients with Primary Biliary Cholangitis of Saroglitazar Magnesium-III
(EPICS-III).2024-518718-14-00Zydus Therapeutics Inc.6